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Abstract
Background: Many major causes of disability in the Global Burden of Disease (GBD) study present with a range of
severity, and for most causes finding population distributions of severity can be difficult due to issues of sparse
data, inconsistent measurement, and need to account for comorbidities. We developed an indirect approach to
obtain severity distributions empirically from survey data.
Methods: Individual-level data were used from three large population surveys from the US and Australia that
included self-reported prevalence of major diseases and injuries as well as generic health status assessments using
the 12-Item Short Form Health Survey (SF-12). We developed a mapping function from SF-12 scores to GBD
disability weights. Mapped scores for each individual respondent were regressed against the reported diseases and
injuries using a mixed-effects model with a logit-transformed response variable. The regression outputs were used
to predict comorbidity-corrected health-state weights for the group of individuals with each condition. The
distribution of these comorbidity-corrected weights were used to estimate the fraction of individuals with each
condition falling into different GBD severity categories, including asymptomatic (implying disability weight of zero).
Results: After correcting for comorbid conditions, all causes analyzed had some proportion of the population in
the asymptomatic category. For less severe conditions, such as alopecia areata, we estimated that 44.1 % [95 % CI:
38.7 %-49.4 %] were asymptomatic while 28.3 % [26.8 %-29.6 %] of anxiety disorders had asymptomatic cases. For
152 conditions, full distributions of severity were estimated. For anxiety disorders for example, we estimated the
mean population proportions in the mild, moderate, and severe states to be 40.9 %, 18.5 %, and 12.3 %
respectively. Thirty-seven of the analyzed conditions were used in the GBD 2013 estimates and are reported here.
Conclusion: There is large heterogeneity in the disabling severity of conditions among individuals. The GBD 2013
approach allows explicit accounting for this heterogeneity in GBD estimates. Existing survey data that have
collected health status together with information on the presence of a series of comorbid conditions can be used
to fill critical gaps in the information on condition severity while correcting for effects of comorbidity. Our ability to
make these estimates may be limited by lack of geographic variation in the data and by the current methodology
for disability weights, which implies that severity must be binned rather than expressed in as a full distribution.
Future country-specific data collection efforts will be needed to advance this research.
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Background
Disability weights are a critical component in estimating
the burden of non-fatal disease, allowing for comparison
of time lived with different conditions in order to quan-
tify years lived with disability (YLDs) [1], and ultimately
for comparability with years of life lost (YLL) to create
the summary composite disability-adjusted life year
(DALY) [2], as well as the health-adjusted life expectancy
[3] summary measure. Disability weights are measured
on a zero to one scale where one is a health state loss
that is equivalent to death and zero represents no func-
tional limitation. The disability weight is meant to cap-
ture the severity of functional limitations in different
domains of health, but not the welfare or social welfare
loss associated with a given health state [4, 5].
For the Global Burden of Disease, Injuries, and Risk
Factors (GBD) 2010 study, disability weights were mea-
sured through general population surveys in five coun-
tries (United States, Peru, Bangladesh, Indonesia, and
Tanzania) as well as through an open internet survey
with participation from 167 countries. The main mode
of measurement used in these surveys was a simple
paired comparison question in which respondents con-
sidered two outcomes described briefly in lay language,
and decided which outcome they regarded as the more
healthy of the pair. Short descriptions were used so that
respondents of varying degrees of educational attain-
ment could comprehend them and make a judgment on
the level of health associated with different states. In
2013, the same methods were applied in web-based sam-
ple surveys among representative population samples
from Hungary, Italy, the Netherlands, and Sweden. For
GBD 2013 the data from the GBD 2010 Disability
Weights Measurement study and European Disability
Weights Measurement study were combined, resulting
in a set of disability weights based on the valuations of
60,890 people [4, 6, 7].
For some conditions, the loss of function described in
the short description captures the typical case of a con-
dition. For example, the health state description for an
amputated toe is straightforward: “has lost one toe, leav-
ing occasional pain and tingling in the stump”. For many
conditions, however, there is a spectrum of severity. The
severity spectrum for a number of conditions such as
chronic obstructive pulmonary disease (COPD), heart
failure, or anxiety disorders was considered in the design
of the study by developing lay descriptions and measur-
ing associated disability weights for more than one level
of severity. To the extent possible, these were based on
standard clinical classification systems.
Empirical measurement of the variation of severity
across individuals using published or unpublished data is
challenging for five main reasons. First, many published
studies on severity distributions use clinical or biometric
criteria and not functional health status measurements.
For example, the New York Heart Association classifica-
tion of heart failure is widely used and, while symptom-
based, is not directly linked to a functional health status
instrument [8]. The same applies to the classification of
major depression and anxiety disorders in ICD-10 or the
Diagnostic and statistical manual of mental disorders
fourth edition (DSM-IV) which are based on symptom
counts. Second, where functional health status data have
been collected, many different instruments have been
used such as EQ-5D [9], the 12-item Short Form (SF-12)
[10], the Health Utilities Index [11], the Assessment of
Quality of Life [12] or a multitude of other disease-
specific quality of life and functioning instruments. Map-
ping between these various instruments and the GBD
disability weights requires an extra empirical step for
which there may be only limited data [13]. Third, well-
characterized [14–16] problems of interpersonal incom-
parability known as differential item functioning across
individuals in functional health status instruments can
complicate the assessment of severity distributions. Dif-
ferential item functioning occurs when respondents
from different groups but living in a similar health state
will give different responses to questionnaires. The pres-
ence of differential item functioning tends to increase
the variance of measured functional health status in a
sample and lead to an increase in the number of individ-
uals reporting severe or no disability for a given condi-
tion. Differential item functioning is likely to be a
greater challenge in this regard with samples that vary in
educational attainment, linguistic, or cultural back-
ground. Fourth, in GBD 2010 disability weights per-
tained to individuals in health states due to one
condition at a time, and therefore empirical severity dis-
tributions from surveys need to be corrected for comor-
bidities. Identifying the marginal severity distribution
due to a condition from measured data requires the use
of some form of statistical model. An alternative would
be to only consider individuals who have a condition of
interest without any comorbidity. With a large number
of health states considered in GBD this would exclude
the majority of respondents and potentially lead to con-
siderable selection bias, and would almost certainly bias
observed severity downward. The need to estimate the
marginal severity distribution limits the use of many
published studies on severity that do not take comorbid-
ity into account, particularly at older ages when comor-
bidity is the norm rather than the exception [17, 18].
Finally, data from clinical cases may be biased because
they likely reflect more severe cases which sought med-
ical attention.
In this paper, we describe the analysis of three large
population sample datasets to supplement information
available in other studies on the distribution of severity
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associated for several conditions in the GBD. The results
here are specific to the GBD 2013 round of estimates.
Conditions were selected if 1) there were little or no
credible data on severity from systematic reviews of the
published and unpublished literature, or 2) data on se-
verity were not easily comparable with GBD health state
descriptions.
Methods
We have taken advantage of three large available data-
sets to estimate severity distributions: the US Medical
Expenditure Panel Survey (MEPS) [19], the National Ep-
idemiologic Survey on Alcohol and Related Conditions
(NESARC) [20], and the 1997 Australian National Sur-
vey of Mental Health and Wellbeing of Adults
(NSMHWB) [21]. MEPS and NESARC have multiple
measurements for the same individual. All three col-
lected functional health status information and provide
information on a broad range of comorbidities. After de-
scribing these datasets in detail, we describe the analysis
in three stages: mapping from SF-12 to GBD disability
weight space, development of a statistical model for indi-
vidual functional health status responses, and estimation
of severity distributions.
Data
The three national surveys collected information using
SF-12 and information on a range of comorbid condi-
tions. The SF-12 questionnaire is a widely used measure
of generic health status. SF-12 is summarized into the
physical and mental component scores (PCS-12 and
MCS-12 respectively), which are standardized to a mean
of 50 and a standard deviation of 10, such that a higher
score represents better physical and emotional func-
tioning. Each summary score corresponds to a four-
week recall period. As its name suggests, the SF-12
asks only 12 questions about functioning but has
been shown to be comparable with the longer 36-
item short form survey [22].
MEPS is a large-scale overlapping continuous panel
survey of the non-institutionalized US population whose
primary purpose is to collect information on the use and
cost of healthcare. Panels are two years long and are
conducted in five rounds, with data collection rounds
every four to six months. A new panel begins every year,
while the previous panel is in its second year [23]. Each
panel typically contains about 30,000 to 35,000 individ-
ual respondents. MEPS was initiated in 1996, but only
began collecting SF-12 responses in 2000, and thus we
only used data from 2000–2010. Data from these years
were pooled for this analysis. Respondents self-
administer the SF-12 twice per panel, at rounds two and
four, typically eight to 12 months apart. Only adults
18 years and older responded to the SF-12. Of these, we
were able to use MCS-12 and PCS-12 scores for 203,960
measurements, taken from 119,676 individuals.
Medical conditions are recorded in MEPS for one of
three reasons: 1) they were reported as a reason for a
medical event, i.e. a health service contact in primary
care or as an inpatient or at the purchase of a drug, 2)
the condition was reported as the reason for one or
more disability days, or 3) the condition was “bothering”
the person during the reference period. The first of these
options is by far the most common source of diagnostic
information. Conditions were recorded as verbatim text
and coded to ICD-9CM three digit codes by professional
medical coders. Error rates per coder are not expected
to exceed 2.5 % [24]. These codes were not validated
with medical providers, though they have been shown to
have high sensitivity. A sensitivity study also found that
rates will improve as condition categories are aggregated
[25]. We mapped ICD-9 codes to 152 categories which
were consistent with the GBD cause list (see mapping in
Additional file 6), this aggregation likely improved the
sensitivity further.
NESARC was conducted in two waves, the first occur-
ring in 2001–2002 and the second in 2004–2005.
NESARC is a representative sample of the non-
institutionalized US population aged 18 and older.
NSMHWB offers a representative sample of adults living
in private dwellings in Australia and was conducted in
1997. Respondents to both surveys were administered
the SF-12.
In NESARC and NSMHWB, conditions were measured
differently than in MEPS. Respondents to the NSMHWB
were diagnosed for mental and substance use disorders via
the Composite International Diagnostic Interview (CIDI), a
standard questionnaire form based on criteria of ICD-10
and DSM-IV [21]. Most mental conditions from NESARC
were diagnosed using an operationalized set of questions
from the DSM-IV using the Alcohol Use Disorder and As-
sociated Disabilities Interview Schedule-IV, or AUDADIS-
IV [20]. MEPS did not use DSM-IV and relied on self-
report of both mental and physical conditions. NESARC of-
fered 12-month prevalence of diagnoses and NSMHWB of-
fered both one month and 12 month diagnoses. We
explore the sensitivity of disability measurements to differ-
ent diagnostic periods later in this paper. Health measure-
ments for 10,641 NSMHWB respondents were used, and
75,656 measurements from 42,494 respondents from
NESARC were used. By design, NESARC and NSMHWB
had collected information on significantly fewer physical
conditions than MEPS. We had information on 26 physical
and mental conditions from NESARC and 17 conditions
from NSMHWB. Correction for comorbidities in these sur-
veys was thus necessarily less comprehensive.
NESARC offered the benefit of splitting up drug de-
pendence categories while still retaining a large enough
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sample in each category. This was particularly useful for
estimating severities in the GBD cocaine, cannabis, and
amphetamine dependence categories [26] (Table 1).
Mapping SF-12 to disability weights
To make use of the extensive data collected using
SF-12 in MEPS, NESARC and NSMHWB for asses-
sing the distribution of severity, individual SF-12 re-
sults had to be mapped to an equivalent disability
weight. SF-12 produces two summary scores, the
MCS and the PCS as noted. To develop a mapping
we selected 62 of the 234 lay descriptions used in
the GBD 2010 disability weight study that repre-
sented the full range of disability weight values cov-
ering the spectrum from most mild (mild distance
vision impairment: “has some difficulty with distance
vision, for example reading signs, but no other prob-
lems with eyesight”, with an associated disability
weight of 0.004) to most severe (active phase of
schizophrenia: “hears and sees things that are not
real and is afraid, confused, and sometimes violent.
The person has great difficulty with communication
and daily activities, and sometimes wants to harm or
kill himself (or herself )”, with an associated disability
weight of 0.763). We used a convenience sample of
respondents to complete the SF-12 form for the
hypothetical individual living in the state described
in each of the 62 conditions; respondents were not
asked to complete the SF-12 for themselves but for
an individual with the health state described in the
lay description. These samples were done at IHME
offices in Seattle and at two GBD training workshops
in Greece. Each respondent completed SF-12 re-
sponses for up to 50 randomly selected states, in
random order, out of the 62. A total of 3,791 re-
sponses were collected.
Disability weights are associated with both mental
and physical disability. To examine the relative contri-
butions of each, we first regressed the GBD disability
weight for each of the states on the MCS and PCS
scores. The coefficients in this regression were
−0.0072 and −0.0045, respectively. However, examin-
ation of the results showed that the states for severe
depression and acute state schizophrenia had only se-
vere MCS limitations which were driving these coeffi-
cients. Exclusion of these two states showed that the
coefficients were −0.0055 and −0.0056 for MCS and
PCS respectively. The nearly equal coefficients imply
that MCS and PCS scores contribute about equally to
the disability weights. To simplify the mapping of
continuous MCS and PCS scores into the disability
weight space needed for this analysis, we combined
the MCS and PCS scores into an overall score
through simple addition as is commonly done with
SF-12.
Given some outliers in the responses, we chose to
use the trimmed mean score for each lay description
group, first by excluding all responses that were
more than two median absolute deviations (MAD)
from the median within each lay description group.
650 observations (19 %) were dropped in this step,
53.8 % from the low end and 46.2 % from the high
end. After correcting for outliers, the simple rank
order correlation mean DW and mean SF-12 was
−0.706. The relationship was not linear. To generate
a smooth mapping from SF-12 combined scores to
the GBD disability weight space, we used loess re-
gression on the trimmed mean SF-12 score for each
health state. Loess fits simple models to localized
subsets of the data in order to explain the variation
point by point, and thus allows us to define a func-
tion that is not restricted by a pre-defined form. Be-
cause disability weights are defined in the range
from zero to one, we truncated the derived function
at a combined SF-12 score of 116.34 (any combined
score above this level was set to 0) and truncated
the function at 43.0 so that any combined score less
than that value was set to 1. This truncation affected
6.0 % of the observations in the population survey
data described in the following subsection. See
Additional file 1 for a list of lay descriptions and
their associated disability weights and mean SF-12
Table 1 Number of respondents by age, sex, and dataset to be
included in the analysis. Each MEPS and NESARC respondent
averaged 1.9 observations. AHS respondents only had one
observation
MEPS NESARC NSMHWB
age group males females males females males females
18 ‐ 19 2,466 2,488 187 138 120 148
20 ‐ 24 5,028 5,578 1,512 1,587 341 460
25‐ 29 4,884 5,765 1,425 2,011 438 610
30 ‐ 34 5,174 6,072 1,637 2,272 502 639
35 ‐ 39 5,456 6,339 1,856 2,499 578 733
40 ‐ 44 5,631 6,487 2,040 2,668 553 616
45 ‐ 49 5,432 6,393 1,941 2,202 456 528
50 ‐54 4,985 5,793 1,758 2,037 359 489
55 ‐ 59 4,215 4,904 1,417 1,882 351 336
60 ‐ 64 3,290 3,847 1,165 1,481 276 316
65 ‐ 69 2,612 3,097 974 1,286 285 293
70 ‐ 74 2,018 2,654 894 1,323 201 299
75 ‐ 79a 1,725 2,350 754 1,274 245 469
80 + 1,784 3,209 953 1,907
54,700 64,976 18,513 24,567 4,705 5,936
a75‐79 age group is 75+ for NSMHWB
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composite scores. The final function is visualized in
Fig. 1.
Modeling individual functional health status
Using the function described above, we transformed SF-
12 values from the population survey data into equiva-
lent disability weight values. These mapped disability
weights represented each respondent’s total, or cumula-
tive, disability. To compare with condition-specific GBD
disability weights in isolation in order to develop mar-
ginal severity distributions, we modeled total disability
as a composition of individual conditions. Ultimately this
model allowed us to determine the distribution of
condition-specific weights for the populations surveyed.
For internal consistency, we assumed the same multi-
plicative form used for the GBD computation of comor-
bidity corrections; [1] the cumulative individual
disability weight is a multiplicative function of the dis-
ability weights DWc for all conditions c = 1, 2, …, N af-
fecting an individual, such that:
cumulative DW ¼ 1 − ΠNc ¼ 1 1 − DWcð Þ ð1Þ
This multiplicative function is useful because it does
not allow for an individual cumulative weight outside
the bounds of zero and one, and thus the marginal dis-
abling effect of each condition on the individual total re-
duces with each additional condition. A simple algebraic
rearrangement of this formula allows one to retrieve the
condition specific disability weight for each individual-
condition combination.
We modeled the comorbidity-disability relationship
using a mixed-effects model with a logit-transformed
dependent variable. Binary indicator variables were
assigned to each condition, and attributed to individuals’
health measurements if the medical event coincided with
the time the measurement was taken. In MEPS, the con-
dition list refers to the two rounds preceding the SF-12
response. Logit-transforming the outcome variable offers
the benefit of limiting the range of the outcome disabil-

















Fig. 1 Disability weight mapping as regressed on estimated SF-12 scores from survey. Each dot represents a mean Health State weight
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transformed dependent variable defines a multiplicative
relationship between the independent parameters, which
is consistent with the multiplicative model for combin-
ing disability weights for YLD estimation described
above. Disability weights were modeled, for each m
measure of each i individual over N total conditions in
each survey, linearly in logit-space, as follows:
log
cumulative DWi;m
1 − cumulative DWi;m
 
¼ β0 þ β1Condition1i;m þ ⋅⋅⋅
þ βNCondition Ni:m þ Ui þ εi;m ð2Þ
where Condition jim (j = 1, 2, …, N) is a dummy variable
indicating whether measurement m in individual i, has
that condition present, and the Ui term is a random
intercept on individual, to account for individual varia-
tions over multiple individual-measures. The model uses
the only the composition of conditions within each indi-
vidual to explain cumulative disability. We chose not to
include age and sex in the model because we were inter-
ested in the direct effects of conditions alone on health
status, and not in controlling for demographic variables
that precede conditions on the causal pathway of inter-
est, since the allocation of conditions is so dependent on
age and sex. Furthermore, a simpler model without age
and sex allowed us to assess how much of the observed
age pattern of functional health status is accounted for
by a simple comorbidity model in the validation step.
The model was run separately for each survey.
Next, we estimated the effect of each condition in iso-
lation among the population with that condition. We
call this the condition-specific disability. In order to do
this we re-wrote equation 1 such that we could solve for
the condition specific weight of each individual with said
condition:
DWc;i;m ¼ 1 − 1 − cumulative DW^ i;m
1 − counter factual DW^ i;m
;
ð3Þ
where cumulative DŴi,m is the expected value of each
individual measure of total disability as predicted by the
model for each observation. The term counter factual
DŴi,m represents the estimated total disability for each
observation estimated using only the main effects and
excluding the condition of interest. For example, if we
were analyzing COPD, we could estimate the predicted
disability weight for each individual recorded as having
COPD excluding the effect of COPD. This produces an
expected disability for these individuals taking into ac-
count all of their respective comorbidities but not the
condition of interest (the counterfactual). We then re-
moved the counterfactual disability from the predicted
cumulative disability to determine the marginal effect of
the condition of interest for that individual. In other
words, we estimated the condition-specific disability for
each individual-condition combination as the predicted
cumulative individual weight portioning out the effects
of all comorbid conditions.
For this analysis, we did not include the individually
estimated random effects when predicting the counter-
factual. The reason is that many chronic conditions are
present at both waves of the data collection, and the ran-
dom effect incorporates information on the distribution
of severity already, as well as other individual-level vari-
ation perhaps due to differential item functioning. If we
were to include the random effect in the estimation of
the counterfactual we could be underestimating severity
for long-term chronic conditions.
Evaluating equation 3 for each individual, we then
took the mean of condition specific disability weights
over the subset of the population that had the condition
to determine the population mean condition-specific
disability. Uncertainty in these estimates was estimated
using bootstrapping: the process was done 1,000 times
for each condition, re-sampling with replacements each
time.
Validation
For a simple validation, we were interested in seeing if
this approach to predicting average weights would gen-
erally predict the level of total disability at the popula-
tion level. We used the simple multiplicative model
(equation 1) to back-estimate cumulative individual dis-
ability using the estimated condition-specific weights for
each individual, accounting for individual composition
of comorbidities and the model intercept. We included
the intercept to account for the unmeasured disability
from short-term or other conditions that were not in-
cluded in the model. Disability weights that were esti-
mated below zero were necessarily truncated to zero, as
the multiplicative equation can only handle disability
weight values between zero and one. We compared
these estimates to the SF-12 transformed average cumu-
lative individual disability weights for each five year age
group.
Estimating marginal severity distributions
As described above, the model allows us to easily esti-
mate a distribution of condition-specific weights for
each survey using a simple multiplicative formula for in-
dividual comorbidity. We followed these same steps to
estimate distributions of health state-specific severity
distributions, but instead of using the predicted cumula-
tive disability in the numerator, we used the observed
cumulative disability. It was important to use the ob-
served cumulative disability because we wanted our
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estimates of health state-specific disability to reflect the
observed heterogeneity in functional health seen in these
surveys, and not just the distribution produced by differ-
ent numbers of comorbidities, as predicted by the
model. We thus distinguish the term condition-specific
disability (as estimated by the model) from health-state
specific disability (as estimated using the observed data).
Health-state specific disability for each observation was
thus estimated following a slight alteration to equation 3:
Health state DWi;m ¼ 1 − 1 − cumulative DWi;m
1 − counter factual DW^ i;m
ð4Þ
This again gave us a distribution of condition-
associated health-state specific weights amongst the
population with the condition in question. To make this
distribution fit with the GBD framework, we then
binned the population into categories of severity for
which disability weights were defined already by the
GBD DW study. We set cutoffs for the bins at the mid-
point between the DW values for each state. For ex-
ample, if anxiety cases can be binned as asymptomatic,
mild, moderate, or severe, then anything below zero
would be considered asymptomatic, and the cutoffs for
the mild bin would be between zero and the midpoint of
the mild and moderate disability weights; the cutoffs for
moderate cases would be between the mild/moderate
midpoint and the moderate/severe midpoint; severe
cases would be considered anything higher than the
moderate/severe midpoint. See Fig. 3 for an illustration
of this binning using the population with anxiety disor-
ders from MEPS as an example.
Zero arises naturally as the upper cutoff for the
asymptomatic category. Cases were considered asymp-
tomatic for the condition of interest if the predicted
counterfactual weight exceeded the observed individual
cumulative weight. This results in a health state valued
at a number lower than zero. For example, consider the
following fictional example: an individual has anxiety,
depression, and acne, with an observed SF-12 trans-
formed disability weight of 0.13, but the model predicts
the total disability of their comorbid depression and anx-
iety conditions alone to be 0.15. This person’s estimated
acne-associated health state will be −0.02 and would
thus be assumed asymptomatic for acne as we
conceptualize their disability to come the combination
of their comorbid conditions and not acne. The same
person would not be asymptomatic for depression if for
instance their counterfactual depression weight (for acne
and anxiety this time) is only 0.05; then 0.08 disability
will be assigned to the depressive health state. All condi-
tions have the opportunity to ‘claim’ the comorbidity-
corrected residual disability, but the amount they can
‘claim’ depends on the amount of disability estimated to
be attributable to their comorbid conditions.
This analysis was run separately for each survey, and
also separately for the one- and 12-month diagnoses
available in NSMHWB. The two NSMHWB survey
waves allowed us to compare the sensitivity of these re-
sults to diagnostic periods.
Uncertainty in distribution estimates were based off
1,000 bootstrapped datasets. As disability weights also
have measured uncertainty, the 1,000 distributions pro-
duced for each condition were binned for each of the
1,000 draws of GBD disability weights used to make cut-
offs. In this way, we were able to incorporate both
sources of uncertainty.
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Results
Model of functional health status
The results of the model represent mean condition-
specific disability, and while important because they in-
form the counterfactual disability estimates, are not
themselves used to calculate YLDs. Full model results
summaries for each survey are found in Additional files
2 and 3.
In general, estimated condition-specific weights or-
dered themselves in a manner quite consistent with ex-
pectations. Serious cancers, mental disorders, and
serious injuries had the largest estimated effects, indicat-
ing the greatest health loss, while more common and
less serious conditions such as acne, benign prostatic
hypertrophy, and attention-deficit hyperactivity disorder
were toward the bottom of the list. Where comparisons
could be made across surveys, results were somewhat
mixed. For example, all three surveys placed unipolar
major depressive disorder at about 0.08, while MEPS,
NSMHWB, and NESARC placed anxiety at 0.05, 0.06,
and 0.03 respectively. Other conditions had even larger
ranges, for example MEPS estimated the mean effect of
cirrhosis at 0.08, while NESARC estimated it as its lar-
gest effect, at 0.20.
Uncertainty intervals in some estimates were large,
and crossed zero for 46 out of the 152 conditions classi-
fied in the MEPS dataset. Many of these were likely due
to small sample sizes, especially in rarer cancers such as
mouth cancer (mean DW: −0.03 [95 % CI: −0.10 to
0.04], n = 34) and testicular cancer (0 · 02 [95 % CI:
−0.02 to 0.11], n = 42). Estimates for conditions we
would consider similarly disabling a priori, but which
had larger sample sizes, were more stable and realistic.
For example, consider lung cancer (0.14 [95 %CI: 0.10 to
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0.18], N = 439) and prostate cancer (0 · 03 [95 % CI: 0.02
to 0.04], n = 1057). Any measurements that fall below
zero would indicate that individuals with those condi-
tions, on average, were healthier than the mean healthy
population, as represented by the model intercept. Con-
ditions with the highest estimated mean effects from
MEPS were pancreatic cancer (0.29 [95 % CI: 0.10 to
0.47], n = 53) and Alzheimer’s disease (0.20 [95 % CI:
0.15 to 0.25], n = 728). Additional file 2 provides a com-
prehensive list of results for each condition included in
the MEPS model. Additional file 3 lists the same results
for NESARC and Additional files 4 and 5 list results for
the 12 and 1-month diagnoses in NSMHWB,
respecitvely.
The NSMHWB survey asked about one and 12 month
diagnoses for a number of mental conditions. To test
the sensitivity of this analysis to diagnosis period, we ran
the analysis separately for the NSMHWB with one and
12 month diagnoses. Estimated weights for one month
diagnoses from the NSMHWB data were higher than
those with a 12 month diagnosis. One month prevalence
figures were, on average, 18 %, 76 %, 100 %, 13 %, and
32 % higher than 12 month prevalence, for alcohol de-
pendence, anxiety disorders, major depression, dys-
thymia, and drug dependence, respectively. 12 month
diagnosed physical conditions were kept in both analyses
and only varied in the range of −5 % to +10 %. The find-
ings indicate that the SF-12 may be quite sensitive to
diagnosis periods as it reflects over the longer course of
chronic-episodic disorders what the proportion of time
without symptoms is. In other words, for longer term
prevalence measures, individuals who are not currently
symptomatic have a higher probability of being captured.
For most chronic conditions in the GBD, estimation ap-
proaches are more consistent with the use of 12 month
prevalence. For certain conditions, such as major depres-
sion which was modeled on the basis of episodes, one
month was used [27].
Model validation
Figure 2 shows the predicted age pattern using our
model (equation 1) with the MEPS data against the
observed age pattern of disability. After binning the
sample into five-year age groups, the model captures
the steady rise expected in disability with progres-
sion of age. This shows that, at a population level,
for any given age, the quantity and composition of
conditions alone can explain much of the observed
total disability. This highlights the usefulness and
necessity of comorbidity adjustment of condition-
specific weights when calculating severity distribu-
tions, and that the multiplicative model utilized else-
where in GBD is appropriate for this.
Of note, there is a decline in disability around the age
of retirement in the MEPS data that is not reflected by
the trend estimated in the comorbid conditions. This
improvement in self-reported functional health status
around the time of retirement has been described in the
literature [28–30], and reflects a subjective limitation of
self-report that a condition-only model cannot capture.
Fig. 2 Mean predicted and observed disability weights by age bins. Predictions are carried out using equation 1, where the disability weight
given to each condition is that of the mean condition-specific weight as estimated by the model. If the mean weight was negative, the condition
weight was truncated to zero, as negative weights are not compatible with the multiplicative comorbidity equation. Each respondent was also
given a baseline disability of 0.015, the model estimated intercept
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Combined MEPS AHS 1 month AHS 12 month NESARC
Cause Health State Weight Cutoff DW Mean LCI UCI Mean LCI UCI Mean LCI UCI Mean LCI UCI Mean LCI UCI
Ischemic heart disease Asymptomatic 0.000 30.5 % 27.9 % 33.0 % 30.5 % 27.9 % 33.0 %
Ischemic heart disease Mild angina due to ischemic heart
disease
0.033 24.0 % 16.7 % 30.9 % 24.0 % 16.7 % 30.9 %
Ischemic heart disease Moderate angina due to ischemic
heart disease
0.080 12.6 % 8.9 % 16.7 % 12.6 % 8.9 % 16.7 %
Ischemic heart disease Severe angina due to ischemic heart
disease
0.167 33.0 % 27.3 % 39.2 % 33.0 % 27.3 % 39.2 %
Other cardiovascular and
circulatory diseases
Asymptomatic 0.000 18.2 % 15.4 % 21.4 % 18.2 % 15.4 % 21.4 %
Other cardiovascular and
circulatory diseases
Mild heart failure due to other
cardiovascular diseases
0.041 55.4 % 48.6 % 60.8 % 55.4 % 48.6 % 60.8 %
Other cardiovascular and
circulatory diseases
Moderate heart failure due to other
cardiovascular diseases
0.072 9.9 % 7.0 % 13.5 % 9.9 % 7.0 % 13.5 %
Other cardiovascular and
circulatory diseases
Severe heart failure due to other
cardiovascular diseases
0.179 16.5 % 11.7 % 21.2 % 16.5 % 11.7 % 21.2 %
Other cardiovascular and
circulatory diseases
Asymptomatic 0.000 27.5 % 26.6 % 28.5 % 27.5 % 26.6 % 28.5 %
Other cardiovascular and
circulatory diseases
Mild other cardiovascular diseases 0.041 30.2 % 22.8 % 38.6 % 30.2 % 22.8 % 38.6 %
Other cardiovascular and
circulatory diseases
Moderate other cardiovascular diseases 0.072 14.7 % 9.4 % 18.7 % 14.7 % 9.4 % 18.7 %
Other cardiovascular and
circulatory diseases
Severe other cardiovascular diseases 0.179 27.6 % 23.3 % 33.0 % 27.6 % 23.3 % 33.0 %
Acute hemorrhagic
stroke
Asymptomatic 0.000 10.4 % 0.0 % 46.4 % 10.4 % 0.0 % 46.4 %
Acute hemorrhagic
stroke
Acute hemorrhagic stroke severity level
1
0.019 42.1 % 12.5 % 71.4 % 42.1 % 12.5 % 71.4 %
Acute hemorrhagic
stroke
Acute hemorrhagic stroke severity level
2
0.070 22.8 % 0.0 % 53.3 % 22.8 % 0.0 % 53.3 %
Acute hemorrhagic
stroke
Acute hemorrhagic stroke severity level
3
0.316 20.1 % 0.0 % 44.7 % 20.1 % 0.0 % 44.7 %
Acute hemorrhagic
stroke
Acute hemorrhagic stroke severity level
4
0.552 3.9 % 0.0 % 22.2 % 3.9 % 0.0 % 22.2 %
Acute hemorrhagic
stroke
Acute hemorrhagic stroke severity level
5













Table 2 Results of health state severity distribution analysis, as used in the GBD 2013. The cause column represents a GBD cause category, and each row represents a health
state, or sequelae, within that cause. When available, distributions from more than one survey were averaged at the draw level. Certain conditions have been included which
only have one specified severity category in the GBD DW study but which may have asymptomatic cases. For those conditions, such as benign prostate hyperplasia, the final
weight is adjusted for the estimated asymptomatic proportion (Continued)
Chronic hemorrhagic
stroke
Asymptomatic 0.000 10.4 % 0.0 % 46.4 % 10.4 % 0.0 % 46.4 %
Chronic hemorrhagic
stroke
Chronic hemorrhagic stroke severity
level 1
0.019 42.1 % 12.5 % 71.4 % 42.1 % 12.5 % 71.4 %
Chronic hemorrhagic
stroke
Chronic hemorrhagic stroke severity
level 2
0.070 22.8 % 0.0 % 53.3 % 22.8 % 0.0 % 53.3 %
Chronic hemorrhagic
stroke
Chronic hemorrhagic stroke severity
level 3
0.316 20.1 % 0.0 % 44.7 % 20.1 % 0.0 % 44.7 %
Chronic hemorrhagic
stroke
Chronic hemorrhagic stroke severity
level 4
0.552 3.9 % 0.0 % 22.2 % 3.9 % 0.0 % 22.2 %
Chronic hemorrhagic
stroke
Chronic hemorrhagic stroke severity
level 5
0.588 0.8 % 0.0 % 11.1 % 0.8 % 0.0 % 11.1 %
Acute ischemic stroke Asymptomatic 0.000 18.6 % 9.5 % 29.9 % 18.6 % 9.5 % 29.9 %
Acute ischemic stroke Acute ischemic stroke severity level 1 0.019 42.8 % 32.4 % 52.8 % 42.8 % 32.4 % 52.8 %
Acute ischemic stroke Acute ischemic stroke severity level 2 0.070 22.7 % 14.4 % 31.5 % 22.7 % 14.4 % 31.5 %
Acute ischemic stroke Acute ischemic stroke severity level 3 0.316 11.7 % 5.0 % 19.4 % 11.7 % 5.0 % 19.4 %
Acute ischemic stroke Acute ischemic stroke severity level 4 0.552 1.6 % 0.0 % 4.6 % 1.6 % 0.0 % 4.6 %
Acute ischemic stroke Acute ischemic stroke severity level 5 0.588 2.5 % 0.7 % 5.4 % 2.5 % 0.7 % 5.4 %
Chronic ischemic stroke Asymptomatic 0.000 18.6 % 9.5 % 29.9 % 18.6 % 9.5 % 29.9 %
Chronic ischemic stroke Chronic ischemic stroke severity level 1 0.019 42.8 % 32.4 % 52.8 % 42.8 % 32.4 % 52.8 %
Chronic ischemic stroke Chronic ischemic stroke severity level 2 0.070 22.7 % 14.4 % 31.5 % 22.7 % 14.4 % 31.5 %
Chronic ischemic stroke Chronic ischemic stroke severity level 3 0.316 11.7 % 5.0 % 19.4 % 11.7 % 5.0 % 19.4 %
Chronic ischemic stroke Chronic ischemic stroke severity level 4 0.552 1.6 % 0.0 % 4.6 % 1.6 % 0.0 % 4.6 %








Mild endocrine, metabolic, blood, and
immune disorders




Moderate endocrine, metabolic, blood,
and immune disorders




Severe endocrine, metabolic, blood,
and immune disorders
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Uterine fibroids Asymptomatic 0.000 31.5 % 26.0 % 37.4 % 31.5 % 26.0 % 37.4 %
Other gynecological
diseases
Asymptomatic 0.000 34.2 % 33.0 % 35.5 % 34.2 % 33.0 % 35.5 %
Other gynecological
diseases





0.114 13.2 % 8.0 % 19.6 % 13.2 % 8.0 % 19.6 %
Other gynecological
diseases
Severe other gynecological disorders 0.324 6.6 % 4.6 % 8.9 % 6.6 % 4.6 % 8.9 %
Alcohol dependence Asymptomatic 0.000 36.8 % 32.2 % 41.8 % 28.0 % 21.7 % 34.2 % 43.7 % 36.4 % 51.1 % 40.5 % 35.3 % 45.8 % 54.8 % 51.2 % 58.3 %
Alcohol dependence Very mild alcohol dependence 0.123 53.4 % 49.0 % 58.5 % 51.7 % 43.5 % 59.6 % 46.4 % 39.1 % 54.1 % 50.8 % 45.7 % 56.0 % 40.1 % 36.4 % 43.8 %
Alcohol dependence Mild alcohol dependence 0.235 3.8 % 2.2 % 5.8 % 5.3 % 2.0 % 9.0 % 3.7 % 1.0 % 7.4 % 3.3 % 1.3 % 5.4 % 2.0 % 1.1 % 2.9 %
Alcohol dependence Moderate alcohol dependence 0.373 3.4 % 1.6 % 5.3 % 5.8 % 2.4 % 9.6 % 3.4 % 0.9 % 6.9 % 3.0 % 1.4 % 4.8 % 1.6 % 0.8 % 2.6 %
Alcohol dependence Severe alcohol dependence 0.570 2.6 % 0.9 % 5.7 % 9.2 % 3.6 % 16.3 % 2.7 % 0.5 % 6.3 % 2.4 % 0.5 % 5.5 % 1.5 % 0.5 % 3.0 %
Fetal alcohol syndrome Asymptomatic 0.000 28.0 % 21.7 % 34.2 % 28.0 % 21.7 % 34.2 %
Fetal alcohol syndrome Mild fetal alcohol syndrome 0.016 22.2 % 13.7 % 31.3 % 22.2 % 13.7 % 31.3 %
Fetal alcohol syndrome Moderate fetal alcohol syndrome 0.056 24.7 % 17.2 % 32.0 % 24.7 % 17.2 % 32.0 %
Fetal alcohol syndrome Severe fetal alcohol syndrome 0.179 25.1 % 17.9 % 33.7 % 25.1 % 17.9 % 33.7 %
Dysthymia Asymptomatic 0.000 35.0 % 29.6 % 39.7 % 37.8 % 28.8 % 47.5 % 37.4 % 29.1 % 46.0 % 32.5 % 28.8 % 36.5 %
Major depressive
disorder
Asymptomatic 0.000 20.4 % 18.8 % 22.0 % 18.6 % 17.8 % 19.3 % 13.0 % 9.7 % 16.6 % 21.8 % 18.5 % 25.2 % 34.5 % 32.1 % 37.1 %
Major depressive
disorder
Mild major depressive disorder 0.145 63.3 % 57.8 % 69.1 % 60.3 % 54.7 % 65.6 % 59.4 % 49.1 % 68.8 % 61.6 % 55.2 % 68.3 % 50.2 % 45.7 % 54.5 %
Major depressive
disorder
Moderate major depressive disorder 0.396 9.9 % 8.0 % 11.8 % 11.4 % 9.6 % 13.0 % 17.3 % 12.7 % 22.1 % 10.8 % 7.9 % 13.5 % 7.7 % 6.2 % 9.1 %
Major depressive
disorder
Severe major depressive disorder 0.658 6.4 % 3.2 % 11.4 % 9.7 % 5.7 % 15.6 % 10.3 % 3.2 % 19.8 % 5.9 % 1.9 % 11.0 % 7.6 % 4.4 % 12.1 %
Other musculoskeletal
disorders
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0.581 7.3 % 4.1 % 11.9 % 7.3 % 4.1 % 11.9 %
Low back pain (with leg
pain)
Asymptomatic 0.000 21.9 % 20.5 % 23.4 % 21.9 % 20.5 % 23.4 %
Low back pain (with leg
pain)
Mild low back pain with leg pain 0.020 20.9 % 14.5 % 28.6 % 20.9 % 14.5 % 28.6 %
Low back pain (with leg
pain)
Moderate low back pain with leg pain 0.054 28.6 % 22.0 % 34.4 % 28.6 % 22.0 % 34.4 %
Low back pain (with leg
pain)
Severe low back pain with leg pain 0.272 10.5 % 7.8 % 12.6 % 10.5 % 7.8 % 12.6 %
Low back pain (with leg
pain)
Most severe low back pain with leg
pain
0.372 18.1 % 11.8 % 25.1 % 18.1 % 11.8 % 25.1 %
Low back pain (without
leg pain)
Asymptomatic 0.000 26.2 % 25.4 % 26.9 % 26.2 % 25.4 % 26.9 %
Low back pain (without
leg pain)
Mild low back pain without leg pain 0.020 28.7 % 21.2 % 37.4 % 28.7 % 21.2 % 37.4 %
Low back pain (without
leg pain)
Moderate low back pain without leg
pain
0.054 26.2 % 19.1 % 32.6 % 26.2 % 19.1 % 32.6 %
Low back pain (without
leg pain)
Severe low back pain without leg pain 0.272 7.9 % 6.3 % 9.2 % 7.9 % 6.3 % 9.2 %
Low back pain (without
leg pain)
Most severe low back pain without leg
pain
0.372 10.9 % 6.9 % 15.7 % 10.9 % 6.9 % 15.7 %
Neck pain Asymptomatic 0.000 33.9 % 31.9 % 36.0 % 33.9 % 31.9 % 36.0 %
Neck pain Mild neck pain 0.053 45.4 % 38.3 % 50.7 % 45.4 % 38.3 % 50.7 %
Neck pain Moderate neck pain 0.114 7.5 % 4.2 % 12.2 % 7.5 % 4.2 % 12.2 %
Neck pain Severe neck pain 0.229 4.0 % 2.5 % 5.4 % 4.0 % 2.5 % 5.4 %
Neck pain Most severe neck pain 0.304 9.2 % 6.1 % 13.0 % 9.2 % 6.1 % 13.0 %
Other oral disorders Asymptomatic 0.000 34.2 % 32.5 % 35.8 % 34.2 % 32.5 % 35.8 %
Other oral disorders Mild other oral disorders 0.006 29.4 % 22.7 % 36.5 % 29.4 % 22.7 % 36.5 %
Other oral disorders Severe other oral disorders 0.051 36.5 % 29.4 % 43.4 % 36.5 % 29.4 % 43.4 %
Asthma Asymptomatic 0.000 35.9 % 34.3 % 37.5 % 30.3 % 29.2 % 31.3 % 38.9 % 35.9 % 41.9 % 38.5 % 35.3 % 42.1 %
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Asthma Partially controlled asthma 0.036 21.5 % 15.0 % 27.7 % 22.3 % 16.6 % 28.1 % 21.5 % 14.1 % 28.1 % 20.8 % 13.8 % 27.4 %








Mild interstitial lung disease and
pulmonary sarcoidosis




Moderate interstitial lung disease and
pulmonary sarcoidosis




Severe interstitial lung disease and
pulmonary sarcoidosis including heart
failure
0.408 21.6 % 11.5 % 32.7 % 21.6 % 11.5 % 32.7 %
Other pneumoconiosis Asymptomatic 0.000 22.4 % 13.3 % 31.6 % 22.4 % 13.3 % 31.6 %
Other pneumoconiosis Mild other pneumoconiosis 0.019 32.0 % 20.7 % 42.9 % 32.0 % 20.7 % 42.9 %
Other pneumoconiosis Moderate other pneumoconiosis 0.225 12.7 % 4.7 % 23.8 % 12.7 % 4.7 % 23.8 %
Other pneumoconiosis Severe other pneumoconiosis
including heart failure
0.408 32.9 % 19.0 % 47.5 % 32.9 % 19.0 % 47.5 %
Other sense organ
diseases
Asymptomatic 0.000 38.9 % 37.7 % 40.1 % 38.9 % 37.7 % 40.1 %
Other sense organ
diseases
Mild other sense organ diseases 0.006 11.5 % 6.3 % 19.1 % 11.5 % 6.3 % 19.1 %
Other sense organ
diseases
Moderate other sense organ diseases 0.011 28.4 % 21.9 % 34.6 % 28.4 % 21.9 % 34.6 %
Other sense organ
diseases
Severe other sense organ diseases 0.113 21.3 % 15.5 % 28.5 % 21.3 % 15.5 % 28.5 %
Alopecia areata Asymptomatic 0.000 44.1 % 38.7 % 49.4 % 44.1 % 38.7 % 49.4 %
Alopecia areata Mild alopecia areata 0.011 31.9 % 23.3 % 39.7 % 31.9 % 23.3 % 39.7 %
Alopecia areata Severe alopecia areata 0.067 24.0 % 15.5 % 32.5 % 24.0 % 15.5 % 32.5 %
Decubitus ulcer Asymptomatic 0.000 26.3 % 23.8 % 28.8 % 26.3 % 23.8 % 28.8 %
Decubitus ulcer Mild decubitus ulcer 0.011 19.9 % 13.9 % 26.2 % 19.9 % 13.9 % 26.2 %
Decubitus ulcer Moderate decubitus ulcer 0.067 28.9 % 22.8 % 34.8 % 28.9 % 22.8 % 34.8 %
Decubitus ulcer Severe decubitus ulcer 0.405 24.9 % 18.8 % 30.7 % 24.9 % 18.8 % 30.7 %
Dermatitis Asymptomatic 0.000 41.8 % 39.9 % 43.8 % 41.8 % 39.9 % 43.8 %
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Dermatitis Severe contact dermatitis 0.188 8.0 % 5.7 % 12.2 % 8.0 % 5.7 % 12.2 %
Eczema Asymptomatic 0.000 41.8 % 39.9 % 43.8 % 41.8 % 39.9 % 43.8 %
Eczema Mild eczema 0.027 50.1 % 45.5 % 53.2 % 50.1 % 45.5 % 53.2 %
Eczema Moderate eczema 0.188 5.7 % 3.8 % 8.6 % 5.7 % 3.8 % 8.6 %
Eczema Severe eczema 0.576 2.4 % 1.4 % 4.1 % 2.4 % 1.4 % 4.1 %
Cellulitis Asymptomatic 0.000 33.2 % 31.2 % 35.4 % 33.2 % 31.2 % 35.4 %
Cellulitis Mild cellulitis 0.027 46.7 % 40.8 % 51.0 % 46.7 % 40.8 % 51.0 %
Cellulitis Severe cellulitis 0.188 20.1 % 15.7 % 25.8 % 20.1 % 15.7 % 25.8 %
Other skin and
subcutaneous diseases
Asymptomatic 0.000 44.6 % 43.2 % 45.9 % 44.6 % 43.2 % 45.9 %
Psoriasis Asymptomatic 0.000 38.3 % 34.6 % 42.1 % 38.3 % 34.6 % 42.1 %
Psoriasis Mild psoriasis 0.027 50.0 % 44.3 % 54.7 % 50.0 % 44.3 % 54.7 %
Psoriasis Moderate psoriasis 0.188 6.8 % 4.5 % 10.6 % 6.8 % 4.5 % 10.6 %
Psoriasis Severe psoriasis 0.576 4.8 % 3.0 % 7.1 % 4.8 % 3.0 % 7.1 %
Urticaria Asymptomatic 0.000 38.1 % 33.0 % 43.4 % 38.1 % 33.0 % 43.4 %
Urticaria Mild urticaria 0.027 47.8 % 40.3 % 53.9 % 47.8 % 40.3 % 53.9 %
Urticaria Severe urticaria 0.188 14.2 % 9.8 % 20.8 % 14.2 % 9.8 % 20.8 %
Viral warts Asymptomatic 0.000 44.1 % 40.8 % 47.5 % 44.1 % 40.8 % 47.5 %
Viral warts Mild viral warts 0.006 32.1 % 25.6 % 39.4 % 32.1 % 25.6 % 39.4 %
Viral warts Severe viral warts 0.067 23.8 % 17.1 % 29.8 % 23.8 % 17.1 % 29.8 %
Molluscum contagiosum Asymptomatic 0.000 44.1 % 40.8 % 47.5 % 44.1 % 40.8 % 47.5 %
Molluscum contagiosum Mild molluscum contagiosum 0.006 32.1 % 25.6 % 39.4 % 32.1 % 25.6 % 39.4 %
Molluscum contagiosum Severe molluscum contagiosum 0.067 23.8 % 17.1 % 29.8 % 23.8 % 17.1 % 29.8 %
Benign prostatic
hyperplasia
Asymptomatic 0.000 41.5 % 38.7 % 44.4 % 41.5 % 38.7 % 44.4 %
Interstitial nephritis and
urinary tract infections
Asymptomatic 0.000 33.1 % 31.4 % 35.0 % 33.1 % 31.4 % 35.0 %
Interstitial nephritis and
urinary tract infections
Mild interstitial nephritis and urinary
tract infections
0.006 23.5 % 16.3 % 30.7 % 23.5 % 16.3 % 30.7 %
Interstitial nephritis and
urinary tract infections
Moderate interstitial nephritis and
urinary tract infections
0.051 43.4 % 35.9 % 50.4 % 43.4 % 35.9 % 50.4 %
Amphetamine use
disorders
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Amphetamine use
disorders
Mild amphetamine dependence 0.079 38.6 % 23.1 % 54.5 % 38.6 % 23.2 % 54.5 %
Amphetamine use
disorders
Severe amphetamine dependence 0.486 6.5 % 1.0 % 13.8 % 6.5 % 1.0 % 13.8 %
Cannabis use disorders Asymptomatic 0.000 57.9 % 51.4 % 63.3 % 57.9 % 51.5 % 63.3 %
Cannabis use disorders Mild cannabis dependence 0.039 36.1 % 30.6 % 42.3 % 36.1 % 30.6 % 42.3 %
Cannabis use disorders Severe cannabis dependence 0.266 6.0 % 3.6 % 8.4 % 6.0 % 3.6 % 8.4 %
Cocaine use disorders Asymptomatic 0.000 50.4 % 36.5 % 63.8 % 50.4 % 36.6 % 63.7 %
Cocaine use disorders Mild cocaine dependence 0.116 42.8 % 29.7 % 57.9 % 42.8 % 29.8 % 57.7 %
Cocaine use disorders Severe cocaine dependence 0.479 6.8 % 1.7 % 13.2 % 6.8 % 1.8 % 13.1 %
Opioid use disorders Asymptomatic 0.000 52.2 % 41.3 % 62.3 % 52.2 % 41.4 % 62.2 %
Opioid use disorders Mild opioid dependence 0.335 42.0 % 30.8 % 53.6 % 42.0 % 30.8 % 53.5 %
Opioid use disorders Severe opioid dependence 0.697 5.8 % 0.8 % 12.7 % 5.8 % 0.8 % 12.6 %
Anxiety disorders Asymptomatic 0.000 28.3 % 26.8 % 29.6 % 25.0 % 24.3 % 25.9 % 18.2 % 14.7 % 21.5 % 22.1 % 19.1 % 25.1 % 47.8 % 45.9 % 50.1 %
Anxiety disorders Mild anxiety disorders 0.030 40.9 % 33.0 % 47.2 % 44.3 % 35.9 % 50.1 % 41.4 % 32.4 % 50.0 % 43.9 % 34.0 % 51.5 % 34.1 % 29.0 % 38.0 %
Anxiety disorders Moderate anxiety disorders 0.133 18.5 % 13.8 % 23.8 % 18.2 % 13.6 % 24.0 % 24.4 % 17.8 % 31.2 % 21.5 % 16.2 % 28.6 % 9.9 % 7.3 % 12.7 %














Table 2 summarizes results of the severity distribution
analysis across all three surveys. Full severity distribu-
tions were analyzed for 152 conditions. After correcting
for comorbid conditions, all causes we analyzed had
some proportion of the population in the asymptomatic
category. For less severe conditions, such as benign
prostatic hyperplasia or alopecia areata, we estimated
that 41.5 % [95 % CI: 38.7 %-44.4 %] and 44.1 % [38.7 %-
49.4 %] were asymptomatic while for conditions such as
chronic ischemic stroke and anxiety disorders 18.6 %
[9.5 %-29.9 %] and 28.3 % [26.8 %-29.6 %] of cases were
asymptomatic.
The asympotmatic category represents not only the
percentage of individuals with disease and no symptoms
but, given the random timing of the survey relative to
health fluctuations, can also capture the fluctuation in
and out of symptoms over time in the population with
the condition. For example, it is not possible for individ-
uals who are never symptomatic to be diagnosed with
anxiety, but rather that those individuals are not symp-
tomatic all the time. In other words, some proportion of
individuals with diagnosed anxiety in the past year
would not be symptomatic at the time of the survey.
Of the 37 conditions analyzed and used in GBD 2013,
four conditions (dysthymia, other skin conditions, be-
nign prostatic hyperplasia, and uterine fybroids) had
only one GBD health state weight, so the final average
disability weight was simply taken as that health state
weight times the proportion symptomatic. However,
most conditions included in this analysis do have several
defined health states. For example, anxiety disorders are
valuated as mild (mean health state weight = 0.03), mod-
erate (0.13), and severe (0.52). This analysis estimated
the average population proportions in these states to be
40.9 %, 18.5 %, and 12.3 % respectively, leaving 28.3 %
asymptomatic. A histogram of comorbidity-corrected
anxiety weights from MEPS is provided in Fig. 3 to illus-
trate how this is done. Anxiety is commonly comorbid
with depression and a number of other mental health
and substance use disorders [31], meaning that we
would expect the comorbidity correction to push the
distribution downward. Despite the removal of comor-
bidities, a large number of individuals remained on the
higher end of the distribution, the interpretation being
that they had a high anxiety-attributable disability.
One should not assess the severity of any condition
relative to another based on the proportion asymptom-
atic alone. Utlimately, these distributions are used to
take a weighted mean of all disability weights associated
with that condition. These severity-adjusted disability
weights are mutliplied by prevalence to estimate YLDs.
Thus, the final severity-adjusted weight of a health state
also depends on the severity distribution of the symp-
tomatic proportion relative to DW cutoffs from the
GBD study.
The distributions in Table 2 represent the outputs in
the of the analysis as described in the methods section
of this paper which were incorporated into the GBD
2013 round of estimates. It should be noted that for
some causes GBD analysts and collaborating groups may
have added further analytical methods to come to their
results as appropriate to their specific modelling strat-
egies. For example, the group estimating the burden of
Fig. 3 Histogram of estimated health state disability weights for anxiety cases in a MEPS sample. Lines represent cutoffs in severity, moving from
asymptomatic (green), to severe (red). The dark area in each bin represents the proportion of the population with each comorbidity-correct health
state; in this case 25 % asymptomatic, 45 % mild, 18 % moderate and 13 % severe
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low back pain did not include an asymptomatic category
in their analysis, as it did not correspond to their par-
ticular estimation strategy using point prevalence [32].
We were able to draw from more than one of the data
sources for nine conditions. For most others except the
drug use disorder categories we used MEPS only. In
most cases, there was a high level of agreement among
the distributions estimated from the different surveys.
For any condition that was tracked in more than one
survey, the final distribution was taken as a mean across
all estimated distributions at the draw level in order to
incorportate uncertainty from all sources.
DISCUSSION
The severity distributions estimated here from three sur-
veys suggest that a substantial fraction of individuals
who report a condition or meet diagnostic criteria for a
condition such as alcohol use or anxiety disorders show
no demonstrable increase in functional limitation once
comorbidities have been taken into account. For some
this may be surprising but it confirms the underlying
premise motivating this study: that there is substantial
heterogeneity in severity of outcomes which should be
accounted for in making population health estimates. In
applying these empirical findings to DALY estimates as
part of the GBD 2013 Study, we move closer to more ac-
curately describing the non-fatal burden of many dis-
eases. The finding further highlights the need to collect
more detailed information on severity in groups of indi-
viduals with various conditions that fully captures the
range of other comorbidities that may be present and
may be key determinants of the level of reported health
functioning.
A simple multiplicative model of comorbidities ex-
plains much of the observed age pattern of functional
health limitations. In other words, comorbid conditions,
especially when an extensive list is used such as in
MEPS, provide a reasonable accounting of individual
functional impairments. A mapping from SF-12 to dis-
ability weights allows for this analysis to serve as a direct
input into non-fatal outcome estimation in the GBD.
Given the importance for the GBD of assessing marginal
severity distributions for conditions, this opens up the
possibility of more extensive use of functional health sta-
tus information in future efforts at quantifying the bur-
den of disease.
The purpose of this analysis was to distribute cases
into coarse severity bins as defined by the disability
weight study in order to create final severity-weighted
disability weights for conditions whose multiple levels of
severity were already built into the study. It should be
noted that final weighted disability weights are quite
sensitive to the cutoffs used for the bins. In future ana-
lyses, with access to more data, researchers should
consider using the full range of severity reported for
each condition rather than binning into a few categories.
Severity distributions could thus be independent of pre-
defined health state weights.
This study has several key limitations. First, the map-
ping from SF-12 MCS and PCS values into the GBD dis-
ability weight space was based on a few small
convenience samples covering only 62 conditions. All re-
spondents completing these SF-12 responses for the
hypothetical health status lived in Seattle or attended a
GBD workshop in Greece. There may be cultural vari-
ation in the way different individuals may map a lay de-
scription into an SF-12 score which is not explored or
captured in this analysis. Second, this study uses data
from only two countries, the US and Australia.
Generalization of societal values across geography and
populations of different social economic status in apply-
ing disability weights has been a topic of debate [33–35].
Moreover, access to health services is higher in these
two countries compared to many other countries in the
world. Applying the severity distributions from these
two countries to DALY estimates for all world regions
means that we are unable to capture a worse severity
distribution in populations that lack access to health
care interventions that ameliorate symptoms and im-
prove functioning. Unfortunately, these are the only
large samples with both multiple conditions and SF-12
data that we have been able to identify. In the systematic
reviews on the severity distribution for major disabling
diseases the vast majority of data also come from high-
income regions with good access to care and the few
data points from low- or middle-income countries are
often biased also towards people who are under care.
Therefore, the lack of differentiation in severity by access
to care is not just a problem in this analysis but a more
general data source weakness in GBD estimates of non-
fatal disease.
This study is further limited by its reliance on the SF-
12 summary measures to bear the weight of a rather
complicated analysis covering a broad spectrum of con-
ditions. The assumption implicit here is that the PCS
and MCS dimensions capture all health impacts due to
conditions present in the regression. While countless
studies have demonstrated the SF-12’s usefulness as a
tool in measuring health status for a variety of physical
and mental conditions, it is hard to imagine that it can
fully capture within its limited dimensions, and with a
high degree of sensitivity, the different types of health
loss caused by all conditions that we tracked. It is pos-
sible that some conditions could be biased to zero if
their symptoms did not contribute to the health dimen-
sions captured in SF-12. SF-12 could further potentially
bias the results of some conditions if some related im-
portant driving comorbidity was not included; for
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example if depression was not included, anxiety would
look much worse, though we believe this concern is ad-
dressed by the large number of conditions tracked, par-
ticularly in the MEPS dataset.
Care should be taken when interpreting results for
particular conditions. For example, we chose not to in-
clude schizophrenia in this analysis as household surveys
exclude institutionalized and homeless populations and
may further exclude people with schizophrenia differen-
tially by non-response [36]. Hence, for schizophrenia,
GBD analysts chose to rely on pooled estimates of sever-
ity from the epidemiological literature rather than the
results from this analysis [27]. Similarly, household sur-
veys tend to underestimate the true prevalence of drug
dependence, but particularly so for opioid dependence,
in which case GBD analysts for that condition applied
an empircal correction factor [26]. It is up to individual
researchers to undertand the data, methods, and limita-
tions when applying results of analyses such as this to
their causes of interest.
There is great potential in national burden of disease
studies of using multi-round functional health status in-
formation to more precisely and comparably measure
the severity distributions of important conditions in dif-
ferent settings. For GBD, replication of such data collec-
tions in low- and middle-income countries would be
highly desirable as a complement to this analysis of sur-
veys from two high-income countries which we had ac-
cess to. A key design factor for such studies in countries
with less access to health care would be to select an un-
biased sample from the population rather than those
who are receiving care. Such studies should also include
anchoring vignettes or other strategies designed to ad-
just for possible differential item functioning [16].
Existing survey data such as MEPS, NESARC, or
NSMHWB that have collected SF-12 data and informa-
tion on the presence of a series of comorbid conditions
can be used to fill critical gaps in the information on
condition severity. The results provide an empirical basis
for assessing the marginal distribution of severity con-
trolling for comorbidity which is required for the GBD.
The systematic reviews conducted for GBD found that
existing information on severity distribution is scarce or
not harmonious for the majority of disabling chronic
conditions contributing to global YLDs. The analysis of
these three surveys has provided new insight into key as-
pects of making comparable measurements of severity
across a broad range of conditions. Measurement of the
severity of any condition is influenced by co-existing
conditions that have similar symptoms (such as pain, re-
stricted mobility, or mental health symptoms). Ignoring
comorbidity leads to overestimation of severity particu-
larly in conditions that are most common in the elderly
or for mental disorders where comorbidity with another
mental or substance use disorder is common. Addition-
ally, there is always a proportion of cases which report
no disability that can be ascribed to the condition after
correcting for disability from comorbid conditions. For
some conditions, this is more likely due to fluctuation of
symptoms over the course of a disorder rather than
reflecting a sub-set of people with the condition who do
not experience any disability at all. Ignoring this fluctu-
ation in symptoms as many studies measuring severity
do (rarely is an asymptomatic category explicitly mea-
sured) leads to an overestimation of the severity
distribution.
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